EPS for Keryx Biopharmaceuticals, Inc. (KERX) Expected At $-0.13

October 13, 2018 - By Hazel Jackson

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) LogoInvestors sentiment increased to 1.74 in Q2 2018. Its up 0.74, from 1 in 2018Q1. It increased, as 9 investors sold Keryx Biopharmaceuticals, Inc. shares while 26 reduced holdings. 23 funds opened positions while 38 raised stakes. 71.09 million shares or 2.95% less from 73.25 million shares in 2018Q1 were reported.
Comml Bank Of Mellon has 1.06 million shares for 0% of their portfolio. Goldman Sachs Grp holds 0% or 120,538 shares. State Street owns 4.11 million shares. Moreover, Wealthtrust Fairport Lc has 0% invested in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) for 685 shares. Schwab Charles Investment Management has 0% invested in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) for 549,724 shares. Raymond James And Assocs has 12,671 shares. Lpl Limited Liability accumulated 0% or 36,827 shares. New York State Common Retirement Fund accumulated 89,500 shares. Tudor Inv Corp Et Al, Connecticut-based fund reported 10,980 shares. Moreover, Cubist Systematic Strategies Ltd has 0% invested in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). 144,654 were reported by California State Teachers Retirement. 14,795 are owned by Raymond James Financial Ser Advsr. Moreover, Adell Harriman & Carpenter Inc has 0% invested in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) for 57,204 shares. Stifel Financial holds 29,520 shares or 0% of its portfolio. Swiss Retail Bank, a Switzerland-based fund reported 160,600 shares.

Since April 18, 2018, it had 0 buys, and 13 selling transactions for $92,499 activity. $11,241 worth of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) was sold by Holmes Scott A on Monday, April 30. The insider Neylan John F. sold $5,099. $9,074 worth of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) was sold by Carberry Christine A.. 1,667 Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) shares with value of $8,702 were sold by Cameron Kevin J.

Analysts expect Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) to report $-0.13 EPS on November, 6.They anticipate $0.07 EPS change or 35.00 % from last quarter’s $-0.2 EPS. The stock increased 0.94% or $0.03 during the last trading session, reaching $3.22. About 506,388 shares traded. Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has declined 58.70% since October 14, 2017 and is downtrending. It has underperformed by 74.32% the S&P500.

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Ratings Coverage

Among 4 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Keryx Biopharmaceuticals had 4 analyst reports since June 25, 2018 according to SRatingsIntel. The stock has “Hold” rating by Maxim Group on Thursday, June 28. Citigroup maintained it with “Neutral” rating and $4 target in Thursday, August 9 report.

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with renal disease in the United States. The company has market cap of $387.88 million. It markets its lead product Auryxia , an orally available, absorbable, iron medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. It currently has negative earnings. The firm has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan.

More news for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) were recently published by: Nasdaq.com, which released: “New Research Coverage Highlights ICF International, Enphase Energy, Paramount Group, Philip Morris International …” on October 09, 2018. Globenewswire.com‘s article titled: “Keryx Biopharmaceuticals Announces Participation in an Upcoming Investor Conference” and published on October 01, 2018 is yet another important article.

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.